WallStSmart

Abbott Laboratories (ABT)vsQMMM Holdings Limited Ordinary Shares (QMMM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 2362422% more annual revenue ($44.33B vs $1.88M). ABT leads profitability with a 14.7% profit margin vs -1.5%. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

QMMM

Avoid

14

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.39
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued

Intrinsic value data unavailable for QMMM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

QMMM2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.3910/10

Safe zone — low bankruptcy risk

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

QMMM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
519.1x2/10

Trading at 519.1x book value

Return on EquityProfitability
-2.0%2/10

ROE of -2.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : QMMM

The strongest argument for QMMM centers on Debt/Equity, Altman Z-Score.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : QMMM

The primary concerns for QMMM are EPS Growth, Piotroski F-Score, Price/Book.

Key Dynamics to Monitor

ABT profiles as a value stock while QMMM is a turnaround play — different risk/reward profiles.

ABT is growing revenue faster at 4.4% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (51/100 vs 14/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

QMMM Holdings Limited Ordinary Shares

COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA

QMMM Holdings Limited, provides digital media advertising and marketing production services primarily in Hong Kong.

Visit Website →

Want to dig deeper into these stocks?